statnews.com·Apr 10, 2026
CAR-T therapies are increasingly being utilized in autoimmune diseases, while the FDA has rescinded approval for GSK's leucovorin related to a rare brain disorder, influenced by political factors.
CAR-T therapies' expanding application to autoimmune diseases presents a significant opportunity for investment and innovation in healthtech, particularly as these therapies gain mainstream traction. Additionally, the FDA's withdrawal of GSK’s leucovorin underscores the importance of staying attuned to regulatory shifts and political influences that can impact drug approvals and market dynamics.